ProQR Therapeutics (PRQR) Receivables - Other (2013 - 2025)

ProQR Therapeutics has reported Receivables - Other for 13 years, with the latest figure at $372297.1 in Q1 2026.

• Quarterly Receivables - Other fell 79.48% year-over-year to $372297.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $372297.1 (down 79.48% YoY) and the FY2025 annual result came in at $364345.6, down 59.17% from the prior year.
• Receivables - Other grew to $372297.1 in Q1 2026 per PRQR's latest filing, from $364345.6 in the prior quarter.
• Over five years, Receivables - Other peaked at $4.4 million in Q2 2024 and troughed at $364345.6 in Q4 2025.
• A 5-year average of $1.6 million and a median of $1.2 million in 2025 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2023 and 2026: Receivables - Other soared 109.51% in 2023, then plunged 79.48% in 2026.
• Over 5 years, Receivables - Other stood at $382592.8 in 2022, then jumped by 109.51% to $801575.2 in 2023, then grew by 11.32% to $892277.2 in 2024, then slumped by 59.17% to $364345.6 in 2025, then climbed by 2.18% to $372297.1 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $372297.1, $364345.6, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.